Submitted by Novartis
BASEL, SWITZERLAND June 23, 2021 /CSRwire/ -— Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.
The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing the application of artificial intelligence, machine learning and geo-spatial analytics to these data; and expanding access to technology in remote and underserved locations.
“Novartis is committed to applying its expertise and full organizational capability to address major, unresolved global health challenges. With Hewlett Packard Enterprise, we will seek to leverage data, digital and technology capabilities to maximize this impact,” said Lutz Hegemann, Group Head of Corporate Affairs and Global Health at Novartis.
Data-related insights are essential to improve access to healthcare and medicines, especially in low-resource settings, because they enable decision makers to target interventions to achieve the greatest impact. However, data is often unavailable, outdated, incomplete or not in digital form. Novartis and HPE therefore aim to identify and integrate diverse data sources to enable real-time disease insights to inform targeted response strategies.
Disease surveillance solution to help remediate the growing threat of dengue fever
The first use case for the partnership will seek to develop a disease surveillance solution for dengue fever, initially focusing on India. More than 3.9 billion people in over 129 countries are at risk of contracting dengue fever, with an estimated 400 million cases and 40,000 deaths each year. The World Health Organization has identified dengue fever as one of the top ten global health threats.
Together, Novartis and HPE aspire to help remediate the growing threat of dengue fever by developing publicly available insights to help authorities proactively deploy response strategies targeting at-risk populations. The resulting real-world evidence will complement the drug-discovery efforts of the Novartis Institute for Tropical Diseases, which is dedicated to finding new medicines to treat neglected, infectious diseases including Dengue fever.
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” “to accelerate,” “advancing,” “to target,” or similar terms, or by express or implied discussions regarding the activities and efforts described in this media update. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the activities and efforts described in this media update, including the collaboration with HPE, will achieve any of its intended goals, or succeed in the expected time frame or at all. In particular, our expectations regarding the collaboration with HPE could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact firstname.lastname@example.org
# # #
Novartis Media Relations
Novartis External Communications
+41 79 723 3681 (mobile)
Novartis Global Health Communications
+41 79 484 7625 (mobile)
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
More from Novartis